Nicholas Turner

Professor Nicholas Turner is a Consultant Medical Oncologist who specialises in the treatment of breast cancer. He read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School. After completing general medical training in London, he trained in medical oncology at Royal Free and University College Hospitals and completed a PhD at The Institute of Cancer Research in 2006. He joined the Breast Unit of The Royal Marsden as a Consultant in Medical Oncology in 2008.

He is a Team Leader in Molecular Oncology at the Breast Cancer Now Research Centre at the Institute of Cancer Research (ICR). He is Genotyping, Phenotyping and Cancer Evolution Theme Lead for The Royal Marsden and ICR NIHR Biomedical Research Centre.

Professor Turner is the Breast Domain Lead of the Genomics England Clinical Interpretation Partnerships, and has co-chaired of the ASCO/CAP review committee on circulating tumor DNA analysis in patients with cancer. He sits on the organising committees of many international conferences on breast cancer, was the executive chair of the IMPAKT 2015 breast cancer conference, and is a scientific editor of the journal Cancer Discovery. He is Chief Investigator of a number of national and international trials of precision therapy in breast cancer. His research interests include the development of new therapies for breast cancer and using liquid biopsies to deliver more precise treatment for breast cancer.

Amato Giaccia

Professor Amato Giaccia is the Director of the Oxford Institute for Radiation Oncology and has held this position with the University of Oxford since January 2019. Until moving to Oxford he was “Jack, Lulu and Sam Willson Professor in Cancer Biology” in the Stanford University School of Medicine, Professor of Radiation Oncology, Associate Chair for Research & Director of the Division of Radiation & Cancer Biology in the Department of Radiation Oncology at Stanford University, California. He was the Director of Basic Science at the Stanford Cancer Institute and lead the Radiation Biology Program in Stanford’s Cancer Center, and was Director of the Cancer Biology Interdisciplinary Graduate Program. He was awarded an American Cancer Society Junior Faculty Research Award and the Michael Fry Award from the Radiation Research Society for his outstanding contributions on understanding the molecular mechanisms of resistance promoted by the tumor microenvironment. Additionally, he was the recipient of the 2013 ASTRO Gold Medal. In 2015, he was awarded an NIH R35 Outstanding Investigator Award and was inducted into the National Academy of Medicine. He co-authored the sixth, seventh and eighth editions of the textbook, “Radiation Biology for the Radiologist,” with Professor Eric Hall from Columbia.

Stephen Hursting

Dr Stephen Hursting is Professor in the Department of Nutrition at the University of North Carolina (UNC) at Chapel Hill. He is also Professor at the UNC Nutrition Research Institute and the UNC Lineberger Comprehensive Cancer Center. He earned his PhD in nutritional biochemistry and MPH in nutritional epidemiology from UNC-Chapel Hill, and he completed postdoctoral training in molecular carcinogenesis and cancer prevention at the National Cancer Institute (NCI). Prior to joining the UNC faculty in 2014, Dr Hursting was Professor and Chair of the Department of Nutritional Sciences at the University of Texas (UT) at Austin, the McKean-Love Endowed Chair of Nutritional, Molecular and Cellular Sciences in the UT College of Natural Sciences, and Professor of Molecular Carcinogenesis at the UT-MD Anderson Cancer Center (2005-14). He also previously served as Chief of the NCI’s Nutrition and Molecular Carcinogenesis Laboratory Section (2000-2005) and Deputy Director of the NCI’s Cancer Prevention Fellowship Program (1999-2005). His research interests centre on precision nutrition as applied to cancer prevention, particularly the molecular and metabolic mechanisms underlying obesity- cancer associations, and the interplay between obesity, metabolism, host genetics and cancer. Primarily using preclinical models (including human and mouse cell lines, genetically engineered mouse models of cancer, and genetically heterogeneous Collaborative Cross mice) in parallel with human studies, he is currently focusing on the molecular and metabolic changes occurring in response to lifestyle-based (dietary and physical activity); surgical (bariatric surgery), or pharmacologic manipulation of energy metabolism and cell signaling pathways, with emphasis on growth factor signaling pathways, inflammation and the gut microbiome.

Rebecca Fitzgerald

Rebecca Fitzgerald is Professor of Cancer Prevention at the University of Cambridge. Her laboratory is in the MRC Cancer Unit, Hutchison/MRC Research Centre. Rebecca continues to practice medicine and is an Honorary Consultant in Gastroenterology, Addenbrooke’s Hospital Cambridge. She graduated from Cambridge University in 1992, performed a research degree at Stanford University, California (1995-1997) and then undertook specialist clinical training and postdoctoral research at Barts and The London Hospitals (1997-2001) and moved back to Cambridge in 2001. The focus of her research is to improve methods for early detection of oesophageal cancer through better understanding of the molecular pathogenesis. Rebecca was awarded the prestigious Westminster medal and prize for her first proof of concept work on the CytospongeTM and associated assays for diagnosing Barrett’s oesophagus in 2004 and since then this work has received an NHS Innovation prize in 2011 and the BMJ Gastro team of the year award in 2016. She received a Lister Prize Fellowship in 2008 and in 2013 Rebecca was awarded an NIHR Research Professorship to facilitate translational research for patient benefit. She was elected a Fellow of the Academy of Medical Sciences in 2013. Rebecca enjoys teaching and communicating science to the public.  She directs studies for medical students at Trinity College Cambridge and is a Fellow of the Institute for Learning and Teaching. Rebecca is committed to bringing research advances into clinical practice and inspiring other researchers to do likewise.

Mark Ratain

Dr Ratain is a graduate of Harvard College (A.B., 1976) and Yale University School of Medicine (M.D., 1980). His postgraduate training was completed at Johns Hopkins Hospital (Internal Medicine, 1980-3) and the University of Chicago Hospitals (Hematology/Oncology, 1983-6). He has been a faculty member in the Department of Medicine at The University of Chicago since 1986, and is currently the Leon O. Jacobson Professor of Medicine, Director of the Center for Personalized Therapeutics and Chief Hospital Pharmacologist. In addition, he serves as the Associate Director for Clinical Sciences in the University’s Comprehensive Cancer Center, and leads the University of Chicago’s phase I oncology trials program. Dr Ratain is also one of the co-founders of Vi3C (Value in Cancer Care Consortium, www.vi3c.org), and currently serves as its Director and Treasurer. Dr Ratain’s research focuses on the development of new oncology drugs and diagnostics, and he is an international leader in phase I clinical trials, pharmacogenomics, and clinical trial methodology, with over 300 original publications. He served as the first chair of the Steering Committee of the National Institutes of Health Pharmacogenetics Research Network, as well as one of the first co-chairs of the National Cancer Institute Investigational Drug Steering Committee. He currently serves as co-Editor of Pharmacogenetics and Genomics, and is a past Associate Editor of the Journal of Clinical Oncology.  He is the recipient of multiple awards, including the Research Achievement Award in Clinical Pharmacology and Translational Research from the American Association of Pharmaceutical Scientists, the Rawls-Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology and Therapeutics, the Translational Research Professorship from the American Society of Clinical Oncology, a Honorary Fellowship from the American College of Clinical Pharmacology, and the Award in Clinical Excellence from the Pharmaceutical Research and Manufacturers Association Foundation.

Mariano Barbacid

Mariano Barbacid got his PhD in Madrid’s Universidad Complutense (1974) and trained as a postdoctoral fellow at the US National Cancer Institute (1974-78). In 1978 he started his own research group to study the molecular events responsible for the development of human tumours. His work led in the spring of 1982, to the isolation of the first human oncogene and the identification of the first mutation associated with the development of human cancer. These findings, also made independently by two other groups, have been seminal to establish the molecular bases of human cancer. In 1988, he joined Bristol Myers-Squibb where he became Vice President, Oncology Drug Discovery. In this position, he pioneered the development of what we know now as targeted therapies. In 1998, he returned to Madrid to create and direct the Spanish National Cancer Research Center (CNIO). In 2011 he stepped down as Director to concentrate on his own research currently centred on the identification and validation of novel therapeutic strategies against K-RAS mutamt lung and pancreatic tumours. In 2012, he was inducted to the US National Academy of Sciences and in 2014, elected Fellow of the Academy of the American Association for Cancer Research. He holds Honorary Degrees (Doctor Honoris Causa) from the Universidad Internacional Menendez y Pelayo (1995), University of Cantabria (2011) and University of Barcelona (2014). His work has been recognised by several domestic and international awards including the Steiner Prize (Bern, 1988), Ipsen Prize (Paris, 1994), Brupbaher Cancer Research Prize (Zurich, 2005), the Medal of Honour of the International Agency for Cancer Research (Lyon, 2007) and the Burkitt Medal (Dublin, 2017). In 2011, he received an Endowed Chair from the AXA Research Fund (Paris). He is one of the few European scientists to receive two Advanced Grants from the European Research Council (2009 and 2015) since their inception in 2008. To date, Dr Barbacid has authored 310 publications, including 231 original research articles in journals with impact factor. Currently, Dr Barbacid’s Hirsch “h” factor is 114 (Google Scholar) and 107 (Web of Science)

Laurence Zitvogel

Pr L Zitvogel, MD (clinical oncology), PhD (tumor immunology), PU-PH University Paris Saclay (Clinical Biology), graduated in Medical Oncology in 1992. She started her scientific career at the University of Pittsburgh (USA) in 1993. She became Research Director at INSERM and Scientific Director of the Immuno-Oncology program at Gustave Roussy. She is a French pioneer in the field of tumour immunology and cancer immunotherapy. She unravelled two concepts, i) the immunogenic cell death ii) the oncomicrobiotics for cancer immunosurveillance. She was the recipient of many awards (including Translation Research INSERM Prize, the Immuno-Oncology ESMO award 2018, the Brupbacher and Baillet Latour Awards).

Frederic de Sauvage

Frederic de Sauvage obtained his PhD summa cum laude from the Catholic University of Louvain in Belgium. He joined the laboratory of David Goeddel at Genentech as a postdoctoral fellow in 1990 and was hired as a Scientist in 1992. In 1994, Dr de Sauvage’s team at Genentech discovered Thrombopoietin (TPO), the long sought physiological regulator of platelet production. He switched his focus to the Hedgehog pathway in the late 1990s. His work led to the development of vismodegib, a Hedgehog Pathway Inhibitor recently approved for the treatment of metastatic or locally advanced basal cell carcinoma (BCC). Dr de Sauvage has recently turned his attention to studying the role of intestinal stem cells in tumorigenesis. In 2011 he received the Achievement in Advancing Targeted Therapies for Cancer & Melanoma Award from the American Skin Association in recognition for his work for patients with BCC. He was elected fellow of the American association for the Advancement of Science in 2016. Dr de Sauvage is now the vice president of Research-Molecular Oncology at Genentech.

Tags: